Oramed Announces Successful Results of a Exploratory Clinical Study of its Flagship Oral Insulin Capsule
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Oramed Pharmaceuticals Inc. has announced successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.
In parallel to Oramed's main focus in developing an oral insulin capsule for management of Type II diabetes the company is exploring an application of its oral insulin capsule toward cases of uncontrolled Type I diabetics. Unstable or labile diabetes is characterized by recurrent, unpredictable and dramatic blood glucose swings often linked with irregular hyperglycemia and sometimes serious hypoglycemia affecting Type I diabetes patients. This newly completed exploratory study was a proof of concept study for defining a novel indication for ORMD-0801. The encouraging results justify further clinical development of ORMD-0801 capsule application toward management of uncontrolled diabetes.
“This study marks an impressive milestone for Oramed” says Nadav Kidron, CEO of Oramed Pharmaceuticals. “These results suggest a possible novel and unique indication for our oral insulin product in the treatment of Type I diabetes in addition to our main indication for Type II diabetes."
In parallel to Oramed's main focus in developing an oral insulin capsule for management of Type II diabetes the company is exploring an application of its oral insulin capsule toward cases of uncontrolled Type I diabetics. Unstable or labile diabetes is characterized by recurrent, unpredictable and dramatic blood glucose swings often linked with irregular hyperglycemia and sometimes serious hypoglycemia affecting Type I diabetes patients. This newly completed exploratory study was a proof of concept study for defining a novel indication for ORMD-0801. The encouraging results justify further clinical development of ORMD-0801 capsule application toward management of uncontrolled diabetes.
“This study marks an impressive milestone for Oramed” says Nadav Kidron, CEO of Oramed Pharmaceuticals. “These results suggest a possible novel and unique indication for our oral insulin product in the treatment of Type I diabetes in addition to our main indication for Type II diabetes."
